Healthcare - Biotechnology - NASDAQ - US
$ 0.6701
-6.12 %
$ 25.9 M
Market Cap
-0.24
P/E
CASH FLOW STATEMENT
-101 M
OPERATING CASH FLOW
95.1 M
INVESTING CASH FLOW
493 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Athira Pharma, Inc.
| Net Income | -118 M |
| Depreciation & Amortization | 969 K |
| Capital Expenditures | -304 K |
| Stock-Based Compensation | 10.6 M |
| Change in Working Capital | 6.53 M |
| Others | -2.04 M |
| Free Cash Flow | -101 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (117.7) | (95.6) | (54.9) | (20.0) | (5.2) | (5.1) |
| Depreciation & Amortization | 1.0 | 0.8 | 0.5 | 0.3 | 2 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | (0.3) | 2 | 0 |
| Stock Based Compensation | 10.6 | 10.6 | 4.6 | 0.6 | 0.3 | 0.2 |
| Other Operating Activities | (1.2) | (0.2) | 0.5 | 1.7 | 0.5 | 0.2 |
| Change in Working Capital | 6.5 | 11.9 | 6.2 | (6.4) | 0.7 | 0.2 |
| Cash From Operations | (100.8) | (72.5) | (43.1) | (24.1) | (3.7) | (4.5) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (0.3) | (1.1) | (1.6) | (2.3) | 0 | 0 |
| Other Items | 95.4 | 58.8 | (2.5) | (207.7) | 1.5 | 2.0 |
| Cash From Investing Activities | 95.1 | 57.7 | (4.1) | (210.1) | 1.5 | 2.0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 1.7 | 0.9 | 1.3 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.5 | 0.7 | 0.3 | 82.6 | 72 K | 0.2 |
| Cash From Financing Activities | 0.5 | 0.7 | 97.1 | 292.8 | 0.9 | 1.5 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (5.2) | (14.2) | 49.9 | 58.6 | (1.3) | (1.0) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (101.1) | (73.6) | (44.7) | (26.4) | (3.7) | (4.5) |